North Carolina Removed the Structural Friction. What Changes for Emerging DSOs.
We will be discussing this at a our HealthcareGO Pre-Conference Session co-hosted with McGuireWoods LLP Tuesday, September 15, 2026 | Charlotte, North Carolina
I. The Regulatory Shift
Session Law 2026-41 removed the North Carolina Dental Board's advance-review requirement for DSO management arrangements.
For years, that requirement shaped how groups in this state were built. It added time to every structuring decision, introduced uncertainty into transaction timelines, and created a diligence question that out-of-state capital had to price. North Carolina was a market where the structure itself required permission.
That friction is gone. The question for owner-operators is not whether the rules changed. It is what the change does to their growth planning and their capital options.
II. What Changes, and What Does Not
Three things change:
- Timing. Management arrangements no longer wait on board review. Transaction calendars compress.
- Structural flexibility. Groups can design management and equity arrangements to fit their capital strategy rather than a review process.
- Capital entry. DSOs and sponsors that treated North Carolina as a secondary market now have a lower cost of entry. Competition for practices, associates, and management talent increases.
One thing does not change. Removing friction lowers the cost of building a platform in North Carolina. It does not raise the value of a platform that is poorly built. Enterprise value is still determined by unit economics, clinical quality, governance alignment, and whether the structure holds up in diligence.
The practical effect is a shift in the question. It moves from "can we structure this" to "should we, and how."
III. The Decision Facing a Three-to-Four-Location Group
Most of the leaders attending this session are at the same inflection point: three to four locations, profitable, and deciding what comes next. The options are familiar. The order of operations is not.
- Continue building independently. Requires capital, infrastructure, and a governance model that survives the fifth and tenth location.
- Take on a capital partner. Minority equity, private credit, or bank debt each carry different implications for control, cost, and the eventual exit.
- Sell or affiliate. Timing relative to platform maturity determines whether the group transacts as a practice or as an enterprise.
- Reposition for a changed market. With entry barriers lowered, the competitive set in North Carolina looks different than it did twelve months ago.
Each path has a different valuation outcome. Each demands a different structure. The purpose of this session is to make those trade-offs explicit.
IV. Three Seats, Three Perspectives
Samantha Strain, Managing Partner at HealthStream Ventures, will moderate a panel built to cover the full range of the decision:
Dr. Michael Riccobene, DDS became the first DSO in North Carolina to receive an approved management arrangement in 2018, years before this law existed. He has since built that platform to roughly 100 practices across three states. He brings the operator's view of what scale requires.
Tom Creegan, Director at Raymond James, works the upper end of middle-market healthcare M&A. He brings the institutional buyer's view of what capital is paying for and what it discounts.
Brendan Messenheimer, Managing Partner at HealthStream Ventures, directly advises groups at the stage most attendees are in today. He brings the structural view of how a three-location group becomes a platform that transacts on its own terms.
V. Session Details
North Carolina Dental Deregulation Briefing A HealthcareGO Pre-Conference Session Tuesday, September 15, 2026 Charlotte, North Carolina Hosted by McGuireWoods LLP and HealthStream Ventures
Attendance is limited to 30 emerging DSO leaders. A small number of seats remain. If you are an owner-operator in the North Carolina market, or a DSO evaluating entry into the state, contact us directly at flow@hsvllc.com.
HealthStream Ventures is a boutique healthcare advisory and investment banking firm serving emerging DSOs and platform-backed groups in the $5M to $50M revenue range. We design enterprise-ready healthcare platforms that withstand diligence, attract capital, and compound value.